Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model

J Neuroinflammation. 2018 Aug 13;15(1):227. doi: 10.1186/s12974-018-1251-0.

Abstract

Background: The first pathology observed in Parkinson's disease (PD) is 'dying back' of striatal dopaminergic (DA) terminals. Connexin (Cx)30, an astrocytic gap junction protein, is upregulated in the striatum in PD, but its roles in neurodegeneration remain elusive. We investigated Cx30 function in an acute PD model by administering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to wild-type (WT) and Cx30 knockout (KO) mice.

Methods: On days 1 and 7 after MPTP administration, we evaluated changes in astrocytic Cx30, Cx43, glial fibrillary acidic protein, and ionised calcium-binding adapter molecule 1 expression by immunostaining and biochemical analysis. Loss of DA neurons was evaluated by tyrosine hydroxylase immunostaining. Gene expression was analysed using A1, A2, pan-reactive astrocyte microarray gene sets, and M1, M2, and M1/M2 mixed microglial microarray gene sets. Real-time PCR and in situ hybridisation were performed to evaluate glial cell-derived neurotrophic factor (Gdnf) and S100a10 expression. Striatal GDNF protein levels were determined by enzyme-linked immunosorbent assay.

Results: MPTP treatment induced upregulation of Cx30 and Cx43 levels in the striatum of WT and KO mice. DA neuron loss was accelerated in Cx30 KO compared with WT mice after MPTP administration, despite no change in the striatal concentration of methyl-4-phenylpyridinium+. Astrogliosis in the striatum of Cx30 KO mice was attenuated by MPTP, whereas microglial activation was unaffected. Microarrays of the striatum showed reduced expression of pan-reactive and A2 astrocyte genes after MPTP treatment in Cx30 KO compared with WT mice, while M1, M2, and M1/M2 mixed microglial gene expression did not change. MPTP reduced the number of striatal astrocytes co-expressing Gdnf mRNA and S100β protein or S100a10 mRNA and S100β protein and also reduced the level of GDNF in the striatum of Cx30 KO compared with WT mice.

Conclusions: These findings indicate that Cx30 plays critical roles in astrocyte neuroprotection in an MPTP PD model.

Keywords: Astrocyte; Connexin 30; Dopaminergic neuron; MPTP; Parkinson’s disease.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • Animals
  • Annexin A2 / metabolism
  • Astrocytes / drug effects
  • Astrocytes / metabolism*
  • Calcium-Binding Proteins / metabolism
  • Connexin 30 / deficiency*
  • Connexin 30 / genetics
  • Connexin 43 / metabolism
  • Disease Models, Animal
  • Dopamine Plasma Membrane Transport Proteins / genetics
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Gene Expression Profiling
  • Gene Expression Regulation / drug effects*
  • Gene Expression Regulation / genetics*
  • Glial Cell Line-Derived Neurotrophic Factor / metabolism
  • Glial Fibrillary Acidic Protein / metabolism
  • MPTP Poisoning / complications
  • MPTP Poisoning / genetics
  • MPTP Poisoning / pathology*
  • Male
  • Mice
  • Mice, Transgenic
  • Microfilament Proteins / metabolism
  • Neurotoxins / pharmacology
  • Oligonucleotide Array Sequence Analysis
  • S100 Proteins / metabolism
  • Striatonigral Degeneration / etiology
  • Striatonigral Degeneration / metabolism*
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Aif1 protein, mouse
  • Annexin A2
  • Calcium-Binding Proteins
  • Connexin 30
  • Connexin 43
  • Dopamine Plasma Membrane Transport Proteins
  • Gjb6 protein, mouse
  • Glial Cell Line-Derived Neurotrophic Factor
  • Glial Fibrillary Acidic Protein
  • Microfilament Proteins
  • Neurotoxins
  • S100 Proteins
  • S100 calcium binding protein A10
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Tyrosine 3-Monooxygenase